HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Clinical trials for HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY explained in plain language.
Never miss a new study
Get alerted when new HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY trials appear
Sign up with your email to follow new studies for HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat ovarian cancer: drug duo enters phase 2 trial
Disease control OngoingThis study tests whether combining two immunotherapy drugs, ONC-392 and pembrolizumab, can shrink tumors in people with platinum-resistant ovarian cancer. About 58 adults with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer are taking part. The goal is to …
Matched conditions: HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Phase: PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo immunotherapy drug enters human trials for 18 cancers
Disease control OngoingThis early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…
Matched conditions: HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New Antibody-Drug conjugate takes aim at Hard-to-Treat gynaecological cancers
Disease control OngoingThis early-stage trial is testing a new drug called IMGN151 in 256 adults with recurrent gynaecological cancers, including ovarian, endometrial, and cervical cancers. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to cells that have a s…
Matched conditions: HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New pill shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis phase 1b trial tests an experimental oral drug called sovilnesib in 120 people with advanced high-grade serous ovarian cancer that has stopped responding to standard platinum chemotherapy. The goal is to find the safest and most effective dose while monitoring side effects a…
Matched conditions: HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY
Phase: PHASE1 • Sponsor: Volastra Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC